Point72 Hong Kong’s Neuropace NPCE Stock Holding History

Point72 Hong Kong’s Portfolio NPCE Stock Details NPCE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-291	Closed	-$3K	–	2177
2021 Q4	$3K	Buy	+291	New	+$3.78K	﹤0.01%	1763

Other funds holding NPCE

KCK Ltd Hamilton, Bermuda $15.1M AUM 30.14% 1-Year Est. Return

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return

NCM

Nantahala Capital Management New Canaan, Connecticut $2.72B AUM 121.58% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

RCM

Revelation Capital Management Sausalito, California $67.4M AUM

Point72 Hong Kong's NPCE Position: Q1 2022 in Review

Point72 Hong Kong sold out of Neuropace (NPCE) in Q1 2022, closing a stake of 291 shares — an estimated $3K sold.

Point72 Hong Kong first reported a position in NPCE in Q4 2021 and held it in 1 quarter. The position peaked at $3K in Q4 2021. 40 funds tracked by Wall St. Rank hold NPCE as of Q1 2022.

Point72 Hong Kong reported no remaining Neuropace position as of Q1 2022 after selling out during the quarter.
Point72 Hong Kong sold 291 Neuropace shares in Q1 2022, an estimated $3K.
Point72 Hong Kong first reported a position in Neuropace in Q4 2021 and held it in 1 quarter.
Point72 Hong Kong's Neuropace position peaked at $3K in Q4 2021.
40 funds tracked by Wall St. Rank held Neuropace as of Q1 2022.

Based on Point72 Hong Kong's 13F filing for Q1 2022, filed 16 May 2022.